Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 3,500 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, July 19th. The stock was sold at an average price of $56.14, for a total value of $196,490.00. Following the completion of the sale, the director now owns 86,697 shares of the company’s stock, valued at $4,867,169.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Lewis Clayton Jr. Cantley also recently made the following trade(s):
- On Thursday, July 20th, Lewis Clayton Jr. Cantley sold 9,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $56.36, for a total value of $507,240.00.
- On Wednesday, June 14th, Lewis Clayton Jr. Cantley sold 2,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $50.87, for a total value of $101,740.00.
- On Thursday, May 25th, Lewis Clayton Jr. Cantley sold 2,036 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $47.10, for a total value of $95,895.60.
Shares of Agios Pharmaceuticals, Inc. (AGIO) traded down 0.10% during midday trading on Friday, reaching $57.17. The company’s stock had a trading volume of 345,338 shares. The stock’s market cap is $2.76 billion. The stock has a 50-day moving average price of $53.35 and a 200-day moving average price of $50.13. Agios Pharmaceuticals, Inc. has a 52-week low of $35.84 and a 52-week high of $67.74.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) EPS for the quarter, beating analysts’ consensus estimates of ($1.80) by $0.24. The business had revenue of $10.51 million during the quarter, compared to analyst estimates of $9.65 million. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. Agios Pharmaceuticals’s quarterly revenue was down 66.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.64) EPS. Equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post ($6.44) earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. State Board of Administration of Florida Retirement System raised its position in shares of Agios Pharmaceuticals by 0.3% in the first quarter. State Board of Administration of Florida Retirement System now owns 39,473 shares of the biopharmaceutical company’s stock valued at $2,305,000 after buying an additional 126 shares in the last quarter. Bank of Montreal Can raised its position in shares of Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 216 shares in the last quarter. Creative Planning raised its position in shares of Agios Pharmaceuticals by 1.4% in the second quarter. Creative Planning now owns 16,710 shares of the biopharmaceutical company’s stock valued at $860,000 after buying an additional 228 shares in the last quarter. Nationwide Fund Advisors raised its position in shares of Agios Pharmaceuticals by 5.2% in the first quarter. Nationwide Fund Advisors now owns 10,104 shares of the biopharmaceutical company’s stock valued at $590,000 after buying an additional 500 shares in the last quarter. Finally, Teachers Advisors LLC raised its position in shares of Agios Pharmaceuticals by 2.3% in the first quarter. Teachers Advisors LLC now owns 30,258 shares of the biopharmaceutical company’s stock valued at $1,767,000 after buying an additional 666 shares in the last quarter. 83.83% of the stock is owned by hedge funds and other institutional investors.
AGIO has been the subject of a number of research analyst reports. BidaskClub upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 13th. Oppenheimer Holdings, Inc. set a $75.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, June 11th. Cann reiterated a “buy” rating and issued a $75.00 target price on shares of Agios Pharmaceuticals in a report on Sunday, June 11th. Canaccord Genuity set a $90.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, May 18th. Finally, Zacks Investment Research upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, April 28th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Agios Pharmaceuticals currently has an average rating of “Buy” and an average price target of $62.88.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
